Ilumya: A Breakthrough Treatment for Moderate to Severe Plaque Psoriasis
What is Ilumya?
Ilumya, also known as tildrakizumab, is a biologic medication used to treat moderate to severe plaque psoriasis. It is a monoclonal antibody that targets the interleukin-23 (IL-23) protein, which plays a key role in the development of psoriasis.
How Does Ilumya Work?
Ilumya works by blocking the action of IL-23, a protein that promotes inflammation and contributes to the development of psoriasis. By inhibiting IL-23, Ilumya reduces the production of inflammatory cytokines, which are molecules that promote inflammation and tissue damage.
History of Ilumya
Ilumya was developed by Sun Pharma, a global pharmaceutical company, and was approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of moderate to severe plaque psoriasis.
Clinical Trials
Ilumya has undergone extensive clinical trials to demonstrate its safety and efficacy in treating plaque psoriasis. In a phase 3 clinical trial, Ilumya was shown to be effective in reducing the severity of psoriasis symptoms, including the number of psoriatic plaques and the severity of skin inflammation.
Benefits of Ilumya
Ilumya offers several benefits for patients with moderate to severe plaque psoriasis, including:
* Improved skin clearance: Ilumya has been shown to improve skin clearance in patients with moderate to severe plaque psoriasis.
* Reduced inflammation: Ilumya reduces inflammation and tissue damage associated with psoriasis.
* Increased quality of life: Ilumya has been shown to improve quality of life for patients with moderate to severe plaque psoriasis.
Side Effects of Ilumya
Like all medications, Ilumya can cause side effects. Common side effects of Ilumya include:
* Injection site reactions: Patients may experience injection site reactions, such as redness, swelling, or itching.
* Upper respiratory tract infections: Ilumya may increase the risk of upper respiratory tract infections, such as bronchitis or pneumonia.
* Headache: Patients may experience headache as a side effect of Ilumya.
Dosage and Administration
Ilumya is administered via injection every 12 weeks. The recommended dosage is 100 mg, which is administered subcutaneously (under the skin).
Cost of Ilumya
The cost of Ilumya can vary depending on the location and insurance coverage. According to DrugPatentWatch.com, the wholesale acquisition cost (WAC) of Ilumya is approximately $1,200 per 100 mg dose.
Conclusion
Ilumya is a breakthrough treatment for moderate to severe plaque psoriasis. Its ability to improve skin clearance and reduce inflammation makes it a valuable option for patients with this condition. While side effects can occur, the benefits of Ilumya make it a worthwhile treatment option for many patients.
Key Takeaways
* Ilumya is a biologic medication used to treat moderate to severe plaque psoriasis.
* Ilumya works by blocking the action of IL-23, a protein that promotes inflammation and contributes to the development of psoriasis.
* Ilumya has been shown to improve skin clearance and reduce inflammation in patients with moderate to severe plaque psoriasis.
* Common side effects of Ilumya include injection site reactions, upper respiratory tract infections, and headache.
* The cost of Ilumya can vary depending on location and insurance coverage.
Frequently Asked Questions
1. Q: What is the recommended dosage of Ilumya?
A: The recommended dosage of Ilumya is 100 mg, administered subcutaneously every 12 weeks.
2. Q: What are the common side effects of Ilumya?
A: Common side effects of Ilumya include injection site reactions, upper respiratory tract infections, and headache.
3. Q: How does Ilumya work?
A: Ilumya works by blocking the action of IL-23, a protein that promotes inflammation and contributes to the development of psoriasis.
4. Q: Is Ilumya available in the US?
A: Yes, Ilumya is available in the US and has been approved by the FDA for the treatment of moderate to severe plaque psoriasis.
5. Q: What is the cost of Ilumya?
A: The cost of Ilumya can vary depending on location and insurance coverage, but the wholesale acquisition cost (WAC) is approximately $1,200 per 100 mg dose.
Sources
1. Sun Pharma. (2020). Ilumya (tildrakizumab) Prescribing Information.
2. FDA. (2018). Ilumya (tildrakizumab) Approval.
3. DrugPatentWatch.com. (2022). Tildrakizumab (Ilumya) Wholesale Acquisition Cost (WAC).
4. ClinicalTrials.gov. (2022). A Study to Evaluate the Efficacy and Safety of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis.
5. National Psoriasis Foundation. (2022). Psoriasis Treatment: Tildrakizumab (Ilumya).